New Zealand markets closed

ARS Pharmaceuticals, Inc. (SPRY)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
8.93+0.10 (+1.13%)
At close: 04:00PM EDT
9.10 +0.17 (+1.90%)
After hours: 07:58PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 865.27M
Enterprise value 641.86M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)85.53k
Price/book (mrq)3.87
Enterprise value/revenue 64.19k
Enterprise value/EBITDA -33.49

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 317.04%
S&P500 52-week change 327.84%
52-week high 311.27
52-week low 32.55
50-day moving average 39.07
200-day moving average 36.58

Share statistics

Avg vol (3-month) 3685.51k
Avg vol (10-day) 3312.59k
Shares outstanding 596.9M
Implied shares outstanding 6100.85M
Float 839.25M
% held by insiders 128.97%
% held by institutions 162.16%
Shares short (30 Apr 2024) 46.38M
Short ratio (30 Apr 2024) 412.25
Short % of float (30 Apr 2024) 412.41%
Short % of shares outstanding (30 Apr 2024) 46.58%
Shares short (prior month 28 Mar 2024) 45.5M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-619,989.99%

Management effectiveness

Return on assets (ttm)-15.54%
Return on equity (ttm)-20.49%

Income statement

Revenue (ttm)10k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -61.94M
Net income avi to common (ttm)-49.7M
Diluted EPS (ttm)-0.52
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)223.63M
Total cash per share (mrq)2.31
Total debt (mrq)217k
Total debt/equity (mrq)0.10%
Current ratio (mrq)60.90
Book value per share (mrq)2.32

Cash flow statement

Operating cash flow (ttm)-53.55M
Levered free cash flow (ttm)-34.37M